Elevance Health (NYSE: ELV) shares ended the last trading session 6.1% higher at $538.48. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.5% loss over the past four weeks. Elevance Health extended its rally for the second straight day, driven by continued optimism over its Health Benefits and Carelon businesses. Baird analyst Michael Ha also initiated coverage of the stock with an Outperform rating, which further drove the stock upward. In Bernstein's 40th Annual Strategic Decisions Conference, ELV mentioned accelerating services and capabilities in its Carelon segment, which is expected to enhance its top line in the second half ...